Bioage Labs, INC 10-Q quarterly reports

BioAge Labs, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased operating expenses, particularly in research and development, alongside continued net losses.

BioAge Labs reports Q1 2026 financial results, highlighting progress on its BGE-102 clinical program and a strengthened cash position.

BioAge Labs, Inc. reported its third-quarter 2025 financial results, highlighting progress in its BGE-102 and APJ agonist programs for metabolic diseases, alongside a significant collaboration revenue increase from Novartis.

BioAge Labs, Inc. reported increased losses and R&D expenses in Q2 2025, driven by new program development and a significant Novartis collaboration, while extending its cash runway through 2029.

BioAge Labs reports its Q1 2025 financial results, highlighting the advancement of its BGE-102 NLRP3 inhibitor program for obesity and a collaboration with Novartis.

BioAge Labs reports a significant increase in cash and cash equivalents to $334.5 million following its initial public offering in the third quarter of 2024, while continuing to advance its clinical programs.